A Phase 1 Study of ABT-767 in BRCA1 or BRCA2 Mutation Carriers With Advanced Solid Tumors and in Subjects With High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Trial Profile

A Phase 1 Study of ABT-767 in BRCA1 or BRCA2 Mutation Carriers With Advanced Solid Tumors and in Subjects With High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Jan 2018

At a glance

  • Drugs ABT 767 (Primary)
  • Indications Breast cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Abbott Laboratories; AbbVie
  • Most Recent Events

    • 08 Jan 2018 Results assessing tolerability, pharmacokinetics and pharmacodynamics of ABT 767 in patients with BRCA1- or BRCA2-positive advanced solid tumours or high-grade serous ovarian, fallopian tube or primary peritoneal cancer, were published in the Investigational New Drugs.
    • 28 Dec 2017 Status changed from active, no longer recruiting to completed.
    • 20 Oct 2017 Planned End Date changed from 31 Dec 2017 to 15 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top